Actavis Specialty Brands has acquired worldwide rights for Valeant's Metronidazole 1.3% vaginal gel antibiotic development product for approximately $55m. Metronidazole 1.3% vaginal gel antibiotic development product is a topical ...
Tags: Actavis, Metronidazole, Gel Antibiotic
Ipsen's Dysport has received marketing authorization from Health Canada for use in aesthetic medicine in the region. A division of Valeant Pharmaceuticals named Medicis Aesthetics Canada will market Dysport in the region. Ipsen's group ...
Tags: Health, aesthetic medicine
Actavis and Valeant Pharmaceuticals have entered into an agreement under which Actavis will market and distribute Valeant's authorized generic of Zovirax ointment (acyclovir 5%) product in the US. As per the agreement of Zovirax ointment, ...
Tags: Actavis, Valeant, Pharmaceuticals
The US FDA has granted final approval for Mylan Pharmaceuticals' abbreviated new drug application (ANDA) for Acyclovir Ointment USP, 5%. Acyclovir Ointment is the generic equivalent to Zovirax Ointment from Valeant International. Mylan ...
Tags: FDA, Acyclovir Ointment, Medicine
Rising Pharmaceuticals, a finished dosage form generics subsidiary of ACETO, has launched 500 mg strength (microsize) of Griseofulvin tablets, which are generic equivalent to Valeant Pharmaceutical's FDA approved Grifulvin. Griseofulvin ...
Tags: Tablet, Pharmaceuticals, Griseofulvin, FDA
The US Food and Drug Administration (FDA) has granted regulatory approval to Actavis' Diltiazem Hydrochloride (HCL) extended-release capsules. Actavis' Diltiazem HCL capsules are generic equivalent of Valeant's cardiovascular drug, ...
Tags: FDA, Actavis generic, cardiovascular drug
Valeant Pharmaceuticals has signed an agreement to obtain certain assets from Atlantis Pharma, including products in the gastro, analgesics and anti-inflammatory therapeutic categories, for approximately $71m. The transaction is expected ...
Tags: Valeant Pharmaceuticals, analgesics, anti-inflammatory therapeutic
Valeant Pharmaceuticals has entered into agreement with Medicis Pharmaceutical to acquire all of the outstanding common stock of Medicis for $44.00 per share in cash. The transaction, which values Medicis's common stock nearly $2.6bn, ...
Tags: transaction, dermatology, clinical product
Valeant Pharmaceuticals has reported a net income of $7.64m, or $0.02 per diluted share, for the third quarter ended 30 September 2012 compared to $40.86m, or $0.13 per diluted share, for the third quarter ended 30 September 2011. Total ...
Valeant Pharmaceuticals has signed an agreement to buy OraPharma, an oral health company, from Water Street Healthcare Partners. The total acquistion value is considered to be $312m and around $114m based on certain pre-determined ...
Tags: Valeant Pharmaceuticals, buy, OraPharma, oral health
Valeant Pharmaceuticals has purchased Pedinol Pharmacal and the transaction is expected to be immediately accretive. Pedinol Pharmacal is a podiatry-focused, privately-owned specialty pharmaceutical company based in the US. Valeant ...